PDS Biotechnology (NASDAQ:PDSB – Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.09) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 19, 2026 at 8:00 AM ET.
PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). On average, analysts expect PDS Biotechnology to post ($0.43) EPS for the current fiscal year and ($0.19) EPS for the next fiscal year.
PDS Biotechnology Price Performance
Shares of PDS Biotechnology stock opened at $1.08 on Tuesday. PDS Biotechnology has a fifty-two week low of $0.20 and a fifty-two week high of $1.79. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 2.73. The stock has a 50 day moving average of $0.93 and a 200 day moving average of $0.84.
Analyst Upgrades and Downgrades
PDSB has been the topic of a number of research analyst reports. Wall Street Zen upgraded PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Monday, October 5th. B. Riley Financial reiterated a “buy” rating and set a $4.00 price target (up from $3.00) on shares of PDS Biotechnology in a report on Thursday, October 29th. HC Wainwright reissued a “buy” rating on shares of PDS Biotechnology in a research report on Wednesday, August 26th. Finally, Weiss Ratings raised PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 28th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $9.50.
Check Out Our Latest Research Report on PDS Biotechnology
About PDS Biotechnology
PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company’s research is based primarily on its Versamune platform, a proprietary technology designed to stimulate targeted immune responses, including the activation of cancer-fighting T cells and natural killer cells.
Its lead investigational product, PDS0101, is an immunotherapy candidate designed to target human papillomavirus type 16 (HPV16), a viral strain associated with several cancers.
Read More
- Five stocks we like better than PDS Biotechnology
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
